相关实验视频

Updated: Jan 16, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

在CLL复杂的遗传景观:临床影响患者的生存和洞察改变的分子路径的洞察力

Carlo Caputo¹, Massimo Donadelli², Mariateresa Scupoli²

¹Department of Precision Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.

Molecular therapy. Oncology

|October 2, 2025

概括

慢性淋巴细胞白血病 (CLL) 的分子表征显示了TP53和KIT基因突变. 某些TP53突变,如Pro72Arg,是常见的SNP,与生存有关,而KIT突变与未接受治疗的患者的良好结果相关.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
分子生物学分子生物学

背景情况:

慢性淋巴细胞白血病 (CLL) 呈现出复杂的分子特征.
了解基因突变对于预测CLL预后和治疗反应至关重要.

研究的目的:

在CLL患者中进行液体活检的分子表征.
识别和分析特定基因突变 (包括TP53和KIT) 对患者生存和临床结果的影响.

主要方法:

从137名CLL患者和10名健康受试者的液体活检分析.
单核酸多态 (SNP) 突变的识别和分类,重点是TP53 (Pro72Arg,Arg337Cys) 和KIT (Met541Leu).
基于突变状态和Binet分期 (A,B,C) 的比较生存分析.

主要成果:

在大多数患者中发现了Pro72Arg TP53 SNP突变,并且与未接受治疗的个体的整体存活率更高有关.
一种罕见的TP53Arg337Cys SNP突变与临床结果有很强的正相关性.
一个KIT Met541Leu突变显著与未经治疗的CLL患者的良好结果相关.
与Binet A患者相比,Binet C期CLL患者的生存率显著降低.

结论:

TP53和KIT基因突变在CLL的分子格局和预后中发挥着重要作用.
特定的TP53SNP,如Pro72Arg和Arg337Cys,以及KIT突变可能作为重要的预后标志物.
需要进一步研究这些突变对p53稳定性和功能的功能影响.

关键词:

在 CLL CLL 中.MT: 定期发行定期发行化学免疫疗法化学免疫疗法基因组异常的基因组异常分子结构分子结构突变特征突变特征测序的测序是指测序的测序.幸存率幸存率生存率

更多相关视频

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...